Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...

Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust ...

Lexaria Bioscience (LEXX) announced the engagement of a contract research organization to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda injectable ...

As a result of the stronger than expected performance of DehydraTECH-processed liraglutide, the Company has made the decision to investigate further with human study GLP-1-H25-5 expected to be ...

As reported on November 20th in Lexaria’s 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide – administered orally - demonstrated a 5.88% weight ...

Semaglutide and liraglutide also linked to reduction in risks for SUD hospitalization, somatic hospitalizations. (HealthDay News) — Semaglutide and liraglutide are associated with a reduced risk ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, is proud to announce its inclusion on the Inc. 2024 Best in ...

In this study, Park et al. investigated the metabolic profiles induced by liraglutide in diet-induced obese mice. This research focuses on uncovering the diverse metabolic changes induced by ...

Insider Buying and Selling at Hims & Hers Health In other Hims & Hers Health news, CFO Oluyemi Okupe sold 101,993 shares of the firm’s stock in a transaction dated Monday, November 25th. The ...